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Abstract 
Due to misunderstandings on their effectiveness and feasibility, topical (or rectal) therapies 
with aminosalicylates (5-aminosalicylic acid, 5-ASA) and steroids are often underused in 
patients with ulcerative colitis (UC). However, many of these patients can be treated solely 
with rectal/topical therapies, or can profit from combined oral and rectal/topical therapies. 
We review the evidence for topical therapies containing 5-ASA and budesonide in UC and 
discuss how topical therapies can be optimized in daily practice, thereby improving 
compliance. Finally, studies with both promising and negative results with other topical 
treatments in UC are shortly summarized.  
 
Introduction 
UC is characterized by a continuous inflammation of the colonic mucosa starting from the 
rectum. Extent of the disease can vary from proctitis to left sided colitis and extensive 
colitis or pancolitis. In most patients, only the distal colon is affected[1-3]. 50-60% of patients 
have a proctosigmoiditis, 20-30% a left-sided colitis up to the splenic flexure, and only 20% 
have an extensive or pancolitis. This distribution and the mucosal inflammation allow the 
use topical therapies with a good clinical response or even remission in most of UC 
patients. Topical therapies containing budesonide and 5-ASA can be used both for 
induction and maintenance of remission.  
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Topical therapies can be applied by suppositories for the rectum in case of proctitis and by 
enemas (liquid) or foam preparations in case of proctosigmoiditis and left sided colitis. The 
distribution of topical therapies has been studied by γ-scintigraphy showing a distribution of 
enemas up to and sometimes even further than the splenic flexure[4, 5]. Foams seem to 
distribute more continuously in the rectum and sigma, but they probably do not reach as 
far as liquid enemas[6]. 
 
Induction of remission by topical therapy 
 
In mild to moderate UC, aminosalicylates are first line drugs to be used according to 
evidence based guidelines. 
Ulcerative proctitis is best treated first line with 5-ASA suppositories[7] which target the 
rectal mucosa better than foams or enemas [8]. However, all topical 5-ASA formulations are 
equally efficacious in the treatment of proctitis[9]. Suppositories with 1000 mg 5-ASA are 
effective and seem the most feasible topical therapy[7, 10-12]. Suppositories can induce 
remission in about two third of patients with ulcerative proctitis[13]. A meta-analysis of 11 
studies showed that topical 5-ASA induces remission in 67% in contrast to only 7-11% 
remissions induced by placebo therapy. More than 1000 mg topical 5-ASA do not show a 
further benefit[11]. Topical 5-ASA is clearly more potent in inducing remission than topical 
steroids[14] which are thus second line therapy for patients who are intolerant to topical 5-
ASA therapy (which is rare). If symptoms persist despite adequate topical monotherapy 
with 5-ASA, topical agents should first be combined (topical steroids and 5-ASA) before 
switching to a combination with oral therapy [15].  
 
Left sided colitis should be treated with foam preparations or liquid enemas with  an 
initial dose of at least 2g 5-ASA[16]. Topical formulations available in Europe are 
summarized in Table 1. In Switzerland, topical 5-ASA is available as Asacol® liquid 
enemas (2g and 4g 5-ASA in a volume of  50ml and 100ml, respectively), Salofalk® liquid 
enemas (2g and 4g 5-ASA in a volume of  30ml and 60ml, respectively), or Salofalk® foam 
(1g 5-ASA in a volume of  30ml). If symptoms persist despite adequate topical 
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monotherapy, topical therapy should first be combined (topical steroids and 5-ASA)[15]. In 
Switzerland, only budesonide is available as active drug in steroid-containing enemas 
(Entocort® liquid enema with 2.3mg budesonide in a volume of 115ml, Budenofalk® rectal 
foam with 2mg budesonide in a volume of 30ml). If this does not induce remission, oral 5-
ASA should be added to topical therapies[16] which will further increase the chance of 
inducing remission. Under these conditions, topical therapies should not be stopped as 
frequently seen in daily practice. Even in patients that complain about discomfort, topical 
therapy can be optimized. In moderate left sided UC, it may be advisable to combine oral 
and topical aminosalicyates from the beginning. The combination of oral and topical 5-ASA 
is clearly more effective (88%) as compared to 4g of rectal aminosalicyates (54%) and 
2.4g oral 5-ASA[16]. Indeed, current ECCO guidelines recommend to treat mild to moderate 
left-sided UC initially with topical and oral 5-ASA[7]. 
 
In case of extensive colitis, the treatment strategy is very similar to left-sided colitis. The 
combination of oral and topical 5-ASA therapy should be explored as the topical therapy 
may especially reduce the inflammation at the location which is mainly responsible for the 
patient’s complaints of urgency: the rectum. Indeed, the combination of topical 5-ASA with 
more than 2g of oral 5-ASA has been shown to be substantially more potent to induce 
remission in extensive colitis than oral-only 5-ASA therapy[17] which induces remission in a 
significantly lower proportion of patients. Thus, topical 5-ASA also adds a clear benefit for 
the treatment of extensive colitis. Effectiveness of topical therapies should be evaluated 
after two weeks. However, if a combination of oral and topical 5-ASA is not sufficient for 
mild or moderately active UC, oral/systemic steroid treatment is certainly justified. In 
extensive colitis, the threshold for using systemic steroids should be lower than in left-
sided colitis[7].  
Severe UC needs to be treated by intravenous steroids as first line therapy. The use of 
topical treatment has not been studied in severe UC, but topical application (budesonide or 
5-ASA) may be considered appropriate in addition to intravenous studies if the patient is 
able to retain the rectal therapy for at least 20 min[7]. Some experts, however, state that 
topical therapies should be avoided in case of severe UC since they will not be tolerated. 
In our daily practice this is the case in some but certainly not all patients with severe colitis. 
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Maintenance of remission by topical therapy 
As for induction of remission, aminosalicylates are the mainstay of therapy for the 
maintenance of remission in patients with UC. Topical 5-ASA is effective for proctitis and 
left-sided colitis[7, 13], and is possibly even more effective than oral 5-ASA [7]. Clinical trials 
with rectal 5-ASA preparations for maintenance of remission have been performed with 
various 5-ASA formulations and dosages per day, week or month, respectively [7]. Based 
on the data available, it can be concluded that in most patients, topical therapy is not 
necessary on a daily basis but can be applied less frequently as for example during 7 days 
per month[18] or 2-3 times per week[19]. A clear dose-response relationship with topical 5-
ASA for maintaining remission in distal UC has not been proven[7]. Probably 1g or less of  
topically applied 5-ASA is sufficient to relieve inflammation in distal UC[9].  In clinical 
practice, finding the minimal dosage of 5-ASA for maintenance of remission remains 
difficult. Nevertheless there should be no “one-fits-all” approach with respect to 
maintenance of remission for topical 5-ASA preparations. Predictive factors need to be 
taken into account, such as severity and frequency of flares before the current remission. If 
topical therapy is not working sufficiently, combined oral and topical therapy should be 
considered .  
 
Can mucosal healing be achieved by “only” topical therapies? 
Many experts in the field advocate that mucosal healing should be achieved to gain an 
optimal prognostic benefit in IBD, irrespective of treatment used[20]. According to a recent 
meta-analysis including data from 2513 patients treated with rectal 5-ASA, mucosal 
healing can be achieved in about 50% of UC patients treated with 5-ASA[21].  There was no 
evidence in this meta-analysis that the rate of mucosal healing is different between 5-ASA 
foams and enemas[21]. There is further evidence for the effectiveness in inducing mucosal 
healing by topical 5-ASA as summarized by Sandborn et al.[22] in a recently published post 
hoc analysis. We must conclude from these results that mucosal healing is possible when 
“only” rectal 5-ASA therapies are used in distal colitis. Besides mucosal healing is no 
argument for an aggressive prescription of anti-TNF antibodies which give no guarantee 
for mucosal healing. In ACT2, about 50% achieved mucosal healing under infliximab 
Frei & Rogler, Review Topical Therapies in IBD, Digestion 2012 (Version 2012-07-13) 5 
treatment[20]. Of course, one has to be aware that anti-TNFs are usually given for 
moderate to severe UC and that these data are no head-to-head comparison. 
 
Side effects of topical therapy 
Topical therapies may have disturbing side effects including leakage, problems with 
retention and bloating[11]. Serious complications such as rectal perforation are only 
described on the level of case reports[23] and can be assumed to be absolute rarities. 
Systemic drug-related side effects are rare. Topically applied budesonide (as well as orally 
administered budesonide) has a very low bioavailability of only 10-15%[24] and therefore 
does not show side effects such as cushingoid features or a measurable suppression of 
basal cortisol levels in the vast majority of patients [25, 26]. In contrast those side effects  
occur very frequently with conventional systemic steroids[27].  
Topically applied 5-ASA does not have relevant systemic side effects. Idiosyncratic side 
effects such as interstitial nephritis, myocarditis or pancreatitis are very rare even when 
oral and systemic forms of 5-ASA are used, without a proven relationship between 
duration or cumulative dose and the risk of renal disease [28, 29]. We are not aware of 
published cases of interstitial nephritis induced by topical 5-ASA therapies. However, there 
is one case report on a 5-ASA induced acute pancreatitis after the use of 5-ASA 
suppositories[30]. Besides one case report of a 5-ASA enema-induced relapse of acute 
pancreatits in a patient who already had had a 5-ASA induced acute pancreatitis after oral 
intake of 5-ASA has been published[31]. This higlights that re-exposition with topical 5-ASA 
in case of pancreatitis, myocarditis, epicarditis or interstitial nephritis as well as other forms 
of hypersensitivity reactions to 5-ASA requires a very careful risk/benefit analysis. 
 
Adherence to topical therapy 
As relevant for other therapies, acceptance of and compliance with medication is crucial 
for the success of topical therapy in UC patients. Non-adherence in patients with IBD can 
be as high as 60%[32]. In a study on medication non-adherence in patients with 5-ASA for 
maintenance of remission, the vast majority of patients with a relapse of UC were non-
adherent[32] . Studies have shown that adherence is worse in maintenance therapies (50%) 
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than in short-term IBD therapy[32, 33]. However, most patients with non-adherence simply 
forget to take their medication (as they do very well during remission)[34]. 
Despite problems with compliance and the fact that most patients (80%) prefer oral 
treatment alone[35], it is important to note that most UC patients are willing to use topical 
therapies[36, 37]. However, effectiveness of topical therapy is much less likely if it induces 
too much urgency[37-39]. A Spanish study has shown that 5-ASA suppositories are well 
tolerated and are considered comfortable for treatment of at least one year[5]. For enemas, 
it seems that urgency is associated with a higher volume applied. Thus, most patients 
prefer foam preparations with less volume applied compared to liquid enema 
formulations[40, 41], although  a Cochrane review in 2010 summarized conflicting experience 
in clinical trials [12]. The urgency induced by topical therapies can be explained by the fact 
that the rectal compliance is clearly reduced in patients with active UC[42-44]. We advise to 
take loperamide 2 mg 20 to 30 minutes before applying the enema to reduce urgency, 
although there is no evidence from clinical studies in UC for this approach. However, in a 
trial using loperamide in obese patients during orlistat treatment with loose stools as a side 
effect of orlistat treatment, loperamide had at least some effect on anorectal sphincter 
function[45], but no effect on rectal capacity or compliance. Furthermore, we advise to lay 
down in a left sided or prone position after applying topical therapy. There are no studies 
on how long topical therapy should be retained to be maximally effective. However, even if 
part of the topical therapy is evacuated, it can be assumed that a relevant part of the drug 
will adhere to the mucosa [9]. Thus, patients should be motivated to try topical therapies 
even if they cannot be retained for a long time.  
 
Doctor’s adherence to guidelines and evidence  
A successful topical therapy not only necessitates patient’s adherence but also doctor’s 
adherence to evidence and guidelines. In an interesting survey among Spanish 
gastroenterologists, only 12-17% of gastroenterologists consider topical 5-ASA as therapy 
of choice for distal colitis[46]. Only 31% of gastroenterologists use the combination of oral 
and topical 5-ASA for extensive mild to moderate UC. 
Furthermore, despite evidence that topical 5-ASA is more potent in reducing remission 
than topical steroids[14], 31-47% of gastroenterologists think that rectal steroid are as 
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effective as topical 5-ASA[46]. In an analysis of 12 consecutive patients with UC, Reddy 
and coworkers found that 75% of patients with left sided UC did not have a topical 
therapy[47]. 
 
New or rare indications and strategies for topical therapies 
In patients with Crohn’s proctitis or left sided colitis, one could argue that topical steroids or 
5-ASA might be useful. However, it is important to note that Crohn’s disease is 
characterized by a transmural inflammation which may be more difficult to cure by a topical 
application of steroids. Currently, there are no studies available on the effect of topical 
therapies with 5-ASA or steroids in Crohn’s disease, despite an extensive literature 
research. Furthermore, it must be kept in mind there is as well no evidence for oral 5-ASA 
in Crohn’s colitis. Thus, topical therapies cannot be recommended for Crohn’s proctitis or 
left-sided Crohn’s colitis.  
 
Besides topical therapies with 5-ASA and steroids, some small studies are available with 
conflicting results on new topical therapies in UC. The most promising alternative topical 
therapies include the use of probiotics and fecal transplantation, tacrolimus and eventually 
Alicaforsen. Several other therapeutic strategies have been reviewed by Lawrance[48] and 
are only mentioned briefly in this review. 
  
- Probiotics: There is good evidence for E. coli Nissle in maintenance of remission in 
UC. E. coli Nissle was consecutively studied as a topical preparation in a double-blind 
study with 90 patients with moderate distal UC. Liquid enemas containing 10exp8 
EcN/ml were compared to placebo enemas during a treatment period of 2 weeks. A 
positive effect could only be demonstrated in the per protocol (PP) analysis, but not in 
the intention-to-treat-analysis (ITT) (PP: p = 0.0446, ITT:  p = 0.4430)[49]. 
- Fecal transplantation: Given the complexity of the fecal microbiota, it seems 
reasonable that the approach of fecal transplantation will be more effective than using 
only a single probiotic strain. Fecal transplantation has mainly been done for treatment 
of recurrent Clostridium difficile infection, but also in patients with therapy refractory 
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UC. More than 20 years ago, the first case of fecal transplantation in UC was 
published[50]. Since then, there have been various case reports showing that fecal 
transplantation (having various other names such as “stool transplant”, “fecal transfer”, 
“fecal microbiota transplantation”) can induce remission in UC patients[51]. In Crohn’s 
disease, a pilot study showed no clinical or endoscopic efficacy of fecal transplantation 
in 4 patients [52]. Currently, at least three clinical trials are ongoing to study the efficacy 
of fecal transplantation in UC: 
- NCT01560819  in the United States is a phase I pilot study in 10 pediatric UC and 
CD patients aged 7-12 years. Patients will receive 5 sessions of fecal transplantation 
by enema with faeces from a donor chosen by the family. 
- NCT01545908 in Canada is a phase II study for the induction of remission in active 
UC and aims at enrolling 130 patients. The active arm will be a fecal transplatation 
from a non-related donor, and the placebo enema will be a saline enema.  
- NTR2862 in the Netherlands (”turn trial”) is a placebo-controlled trial in adults aged 
18 years or older and aims at enrolling 40 patients. The active arm will be a fecal 
transplantation from no further specified healthy donor by duodenal-tube infusion, the 
placebo arm will receive their own faeces. 
- Tacrolimus: Tacrolimus is a strong immunosuppressant which is able to induce and 
maintain remission in severely active UC. However, high serum levels are necessary 
to induce remission, which predisposes to drug side effects such as tremor, headache, 
or renal insufficiency. Interestingly, open label studies with (not commercially 
available) topical tacrolimus preparations were able to induce remission in left-sided 
UC at a low dose of 1.8-4mg (either as suppositories, enemas or ointments) and 
without leading to high serum levels of tacrolimus as seen during oral intake[53, 54]. 
There were no relevant side effects observed. Thirteen of 19 patients in one study 
showed a clinical improvement of disease activity after 4 weeks of local tacrolimus 
treatment. The other study reported clinical remission in 6 of 8 patients. These results 
are promising, but a commercially available topical tacrolimus preparation would be 
needed to allow a wide-spread use of this strategy in left-sided colitis.  
- Alicaforsen: In an open-label study with nightly rectal enemas of alicaforsen which is 
an antisense oligodeoxynucleotide against intercellular adhesion molecule 1 (ICAM-1) 
mRNA, 33% of patients reached remission at the end of the 6 week study period[55]. 
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Similarly, 7 of 12 patients using alicaforsen with chronic unremitting pouchitis reached 
remission[56].  These results look very promising, but alicaforsen is still only a 
candidate as orphan drug in Europe. Further randomized trials are clearly warranted.  
 
Several small and sometimes quite old studies analyzed various other therapeutic 
approaches, with sometimes promising but no convincing results allowing their use in 
clinical practice. [48] 
- Liquid enemas with ciclosporin A initially looked promising in open-label studies[57], but 
were not shown to be active in placebo-controlled randomized trials[58].  
- Similarly, Butyrate enemas were promising in open-label studies[59], but not in placebo-
controlled randomized trials[60].  
- Since impaired epithelial expression of peroxisome proliferator-activated receptor χ 
(PPARχ) ligand was described in ulcerative colitis, a topically administered 
Rosiglitazone has been studied in a pilot study and was successful in patients with not 
previously treated IBD patients[61]. However, rosiglitazone has been withdrawn in 2010 
due to cardiovascular side effects. We are not aware of ongoing or planned studies 
with other PPAR Gamma ligands in IBD. 
- Nicotine enemas containing 6mg of nicotine have been studied in a large randomized 
double-blind study including 104 patients with active UC[62]. However, 6mg of topical 
nicotine were not found to be efficacious for active UC. 
- Arsenic suppositories (250mg b.d. for 4 weeks) have been studied in only one small 
study with 10 patients[63]. In 9 of 10 patients, symptoms and endoscopic signs of 
proctitis resolved within 2 weeks, but 6 of 10 patients showed a relevant systemic 
arsenic absorption. Currently, arsenic suppositories are infrequently used.  
- Further therapeutic strategies include the use of lidocaine enemas, Ecabet enemas, 
Epidermal growth factor enemas, remapimide enemas and thromboxane enemas [48]. 
 
Conclusions 
Topical therapies are effective and feasible in proctitis and left-sided colitis for both 
induction and maintenance of remission. If topical therapies are not sufficiently efficacous 
in left-sided UC, they should be combined with and not replaced by oral 5-ASA. Topical 
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budesonide should be used if topical 5-ASA is not effective or in case of intolerance to 
topical 5-ASA which is rare. In extensive colitis, oral and topical 5-ASA should be 
combined. Only in severe UC, topical therapies may be omitted because they lack 
sufficient efficacy and may not be tolerated by patients. There is insufficient evidence for 
the efficacy of topical therapies in Crohn’s disease including Crohn’s colitis. Some new 
topical therapeutics have recently been or are currently studied for the treatment of UC.  
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